Evidence map›Paper›PMID 39270007›Full record

ArticleScience immunology2024

CD4

Steven P Wolf, Matthias Leisegang, Madeline Steiner, Veronika Wallace, Kazuma Kiyotani, Yifei Hu, Leonie Rosenberger, Jun Huang, Karin Schreiber, Yusuke Nakamura and 2 more

Abstract read
In one paragraph

Article in Science immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Idiotype-specific CD4Nature communications · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Steven P WolfDavid and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA.ORCID 0009-0008-2723-695X
Matthias LeisegangDavid and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA.ORCID 0000-0003-3692-7142
Madeline SteinerDepartment of Pathology, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-6201-4390
Veronika WallaceDepartment of Pathology, University of Chicago, Chicago, IL, USA.ORCID 0009-0005-9716-7943
Kazuma KiyotaniProject for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0002-9236-9061
Yifei HuPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.ORCID 0000-0003-2870-7772
Leonie RosenbergerInstitute of Immunology, Charité-Universitätsmedizin Berlin, Campus Berlin Buch, Berlin, Germany.
Jun HuangPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.ORCID 0000-0003-0271-4384
Karin SchreiberDavid and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA.ORCID 0009-0000-1414-9365
Yusuke NakamuraProject for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.ORCID 0000-0003-2956-382X
Andrea SchietingerImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3644-1687
Hans SchreiberDavid and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA.ORCID 0000-0002-1908-6233

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI THOMAS F GAJEWSKI · 1985 to 2026
$122.1M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
PATHOBIOLOGY OF MYELOMA AND ANTI-IDIOTYPIC IMMUNITYR01CA022677 · NCI · UNIVERSITY OF CHICAGO · PI SCHREIBER, HANS · 1985 to 2024
$6.3M
Medical Scientist National Research Service AwardT32GM150375 · NIGMS · UNIVERSITY OF CHICAGO · PI Raghavendra G Mirmira · 2023 to 2026
$5.5M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA022677NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIDA NIH HHS 75N95020D00005NIGMS NIH HHS T32 GM150375ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Cancers eventually kill hosts even when infiltrated by cancer-specific T cells. We examined whether cancer-specific T cell receptors of CD4

Indexed as

CD4-Positive T-LymphocytesImmunotherapy, AdoptiveAnimalsFemaleHumansMiceMice, Inbred C57BLMice, TransgenicReceptors, Antigen, T-CellRecombination, GeneticReceptors, Antigen, T-Cell

Identifiers

PMID39270007
PMCPMC11560124

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.